Marta Ortega-Valle - Feb 2, 2022 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC (GRNA)

Role
Chief Business Officer
Signature
/s/ David Kennedy, Attorney-in-fact
Stock symbol
GRNA
Transactions as of
Feb 2, 2022
Transactions value $
$0
Form type
4
Date filed
2/4/2022, 06:28 PM
Next filing
Aug 8, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GRNA Stock Option (Right to Buy) Award +29.8K 29.8K Feb 2, 2022 Common Stock 29.8K $0.24 Direct F1, F2
transaction GRNA Stock Option (Right to Buy) Award +105K 105K Feb 2, 2022 Common Stock 105K $0.28 Direct F2, F3
transaction GRNA Stock Option (Right to Buy) Award +106K 106K Feb 2, 2022 Common Stock 106K $0.35 Direct F2, F4
transaction GRNA Stock Option (Right to Buy) Award +248K 248K Feb 2, 2022 Common Stock 248K $0.98 Direct F2, F5
transaction GRNA Stock Option (Right to Buy) Award +260K 260K Feb 2, 2022 Common Stock 260K $0.98 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to this option are fully vested and exercisable.
F2 This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company.
F3 100% of the shares subject to this option are fully vested and exercisable.
F4 100% of the shares subject to this option are fully vested and exercisable.
F5 20% of the shares underlying the option vested or shall vest on September 24, 2021 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting October 24, 2021.
F6 25% of the shares underlying the option vested or shall vest on December 1, 2021 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting January 1, 2022.